Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensifentrine Phase II study in non-cystic fibrosis bronchiectasis
2024-514845-12-00Phase 2Authorised
- Sponsor
- Verona Pharma
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing Ensifentrine with Placebo (2 arms). Primary endpoint: Rate of protocol-defined pulmonary exacerbations. Planned start Mar 2025; status: authorised.
02
Drugs
ensifentrine
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2024-514845-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514845-12-00.